Home > Analytics > ASPIRA PATHLAB & DIAGNOSTICS

ASPIRA PATHLAB & DIAGNOSTICS
Intrinsic Value | Fundamental Analysis

BOM : 540788     NSE :     
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward
Pledged Shares : None or < 25%
Jun 02,2026
Price(EOD): ₹ 128.05
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Hospital & Healthcare Services
MCap: ₹ 131.89 Cr
Value of ₹ 1 Lac invested in ASPIRA PATHLAB & DIAGNOSTICS
on Jul 05,2021 (price: ₹ 31.35)

₹ 1 L

₹ 4.08 L

1W : 3.1% 1M : 97.2% 1Y : 141.9%
COMMUNITY POLL
for ASPIRA PATHLAB & DIAGNOSTICS
Please provide your vote to see the results
ASPIRA PATHLAB & DIAGNOSTICS is part of below Screeners ↓
Best 1M Momentum Small Cap Stocks
Industry Peers & Returns1W1M1Y
ASPIRA PATHLAB & DIAGNOSTICS 3.1% 97.2% 141.9%
APOLLO HOSPITALS ENTERPRISE -2% 6% 14.6%
MAX HEALTHCARE INSTITUTE -4.4% -4.4% -19%
FORTIS HEALTHCARE -3.8% 0.7% 31.8%
ASTER DM HEALTHCARE -4.1% 3.7% 31.4%
NARAYANA HRUDAYALAYA 2.3% 9.5% 9.3%
GLOBAL HEALTH -2.5% 7.2% -3.6%
KRISHNA INSTITUTE OF MEDICAL SCIENCES -2.8% 12.1% 15.1%
DR LAL PATHLABS -2.4% 14.2% 10.8%

FUNDAMENTAL ANALYSIS OF ASPIRA PATHLAB & DIAGNOSTICS

 
Fundamentals Score
[ Q(TTM): Jun2025, Y: Mar2025
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]



VALUATION OF ASPIRA PATHLAB & DIAGNOSTICS

 
Valuation Score
[As on : Jun 02,2026 ]

Ratio Consolidated
P/E
P/B
P/S
51.52
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 2.56 Cr
[Latest Qtr - Jun2025 - Consolidated Results ]

10.83
P/B Calculated based on Book Value of Rs 12.17 Cr
[Latest Year - Mar2025 - Consolidated Results ]

5.83
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 22.61 Cr
[Latest Qtr - Jun2025 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 27% undervalued companies ! Discover More →

FAIR VALUE OF ASPIRA PATHLAB & DIAGNOSTICS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
165%
112%
113%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF ASPIRA PATHLAB & DIAGNOSTICS


Insights 💡 ASPIRA PATHLAB & DIAGNOSTICS is one of the top 29% companies with bullish price momentum currently! Discover More →

ASPIRA PATHLAB & DIAGNOSTICS vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF ASPIRA PATHLAB & DIAGNOSTICS

Year Debt/Equity ratio
Standalone Consolidated
2025
2024
2023
Avg_3yrs
0.1
0.11
0.08
0.1
0.1
0.11
-
0.07
[Last Annual Data : Mar2025]
Financial Ratios →

PLEDGED PROMOTER SHARES OF ASPIRA PATHLAB & DIAGNOSTICS

Pledged Promoter Shares
0 %
As on : Mar2026

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF ASPIRA PATHLAB & DIAGNOSTICS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-9.16%
-22.03%
-34.99%
-34.99%
13.18%
134.57%
3037.5%
3037.5%
QtrlyTrend
0
Latest Qtr: Jun2025
Quarterly Result Analysis →


ASPIRA PATHLAB & DIAGNOSTICS related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about ASPIRA PATHLAB & DIAGNOSTICS


Is ASPIRA PATHLAB & DIAGNOSTICS good for long term investment?

As on Jun 02,2026, the Fundamentals of ASPIRA PATHLAB & DIAGNOSTICS look Poor and hence it may not be good for long term investment ! See Financial Performance of ASPIRA PATHLAB & DIAGNOSTICS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is ASPIRA PATHLAB & DIAGNOSTICS UnderValued or OverValued?

As on Jun 02,2026, ASPIRA PATHLAB & DIAGNOSTICS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of ASPIRA PATHLAB & DIAGNOSTICS ?

As on Jun 02,2026, the Intrinsic Value of ASPIRA PATHLAB & DIAGNOSTICS is Rs. 60.12 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 48.35
Fair Value [Median EV / Sales Model] : Rs. 60.41
Fair Value [Median Price / Sales Model] : Rs. 60.12
Estimated Median Fair Value of ASPIRA PATHLAB & DIAGNOSTICS : Rs. 60.12

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is ASPIRA PATHLAB & DIAGNOSTICS trading at a Premium or Discount?

As on Jun 02,2026, ASPIRA PATHLAB & DIAGNOSTICS is trading at a Premium of 113% based on the estimates of Median Intrinsic Value!